Study #2022-0638
An open-label multicenter phase 1b-2 study of elacestrant as monotherapy and in combination with abemaciclib in women and men with brain metastasis from estrogen receptor positive, HER-2 negative breast cancer (ELECTRA)
MD Anderson Study Status
Enrolling
Treatment Agent
Elacestrant, Abemaciclib
Description
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Study phase:
Physician name:
Nuhad Ibrahim
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-363-0789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.